

Hiu-Tat Chan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3913515/publications.pdf>

Version: 2024-02-01

24
papers

485
citations

758635

12
h-index

713013

21
g-index

24
all docs

24
docs citations

24
times ranked

689
citing authors

#	ARTICLE	IF	CITATIONS
1	Bacteriophages in Natural and Artificial Environments. <i>Pathogens</i> , 2019, 8, 100.	1.2	124
2	Australian consensus statements for the regulation, production and use of faecal microbiota transplantation in clinical practice. <i>Gut</i> , 2020, 69, 801-810.	6.1	52
3	Hepatitis E Virus and Implications for Blood Supply Safety, Australia. <i>Emerging Infectious Diseases</i> , 2014, 20, 1940-1942.	2.0	34
4	Genomic, morphological and functional characterisation of novel bacteriophage FNU1 capable of disrupting <i>Fusobacterium nucleatum</i> biofilms. <i>Scientific Reports</i> , 2019, 9, 9107.	1.6	34
5	Hepatitis E virus RNA in Australian blood donations. <i>Transfusion</i> , 2016, 56, 3086-3093.	0.8	27
6	Novel Bacteriophages Capable of Disrupting Biofilms From Clinical Strains of <i>Aeromonas hydrophila</i> . <i>Frontiers in Microbiology</i> , 2020, 11, 194.	1.5	22
7	Characterization and formulation into solid dosage forms of a novel bacteriophage lytic against <i>Klebsiella oxytoca</i> . <i>PLoS ONE</i> , 2017, 12, e0183510.	1.1	21
8	Quantifying complement-mediated phagocytosis by human monocyte-derived macrophages. <i>Immunology and Cell Biology</i> , 2001, 79, 429-435.	1.0	20
9	Semi-Solid and Solid Dosage Forms for the Delivery of Phage Therapy to Epithelia. <i>Pharmaceuticals</i> , 2018, 11, 26.	1.7	20
10	Pilot study of a combined genomic and epidemiologic surveillance program for hospital-acquired multidrug-resistant pathogens across multiple hospital networks in Australia. <i>Infection Control and Hospital Epidemiology</i> , 2021, 42, 573-581.	1.0	18
11	Lytic Bacteriophage EFA1 Modulates HCT116 Colon Cancer Cell Growth and Upregulates ROS Production in an <i>Enterococcus faecalis</i> Co-culture System. <i>Frontiers in Microbiology</i> , 2021, 12, 650849.	1.5	16
12	Utilizing genomic analyses to investigate the first outbreak of van A vancomycin-resistant <i>Enterococcus</i> in Australia with emergence of daptomycin non-susceptibility. <i>Journal of Medical Microbiology</i> , 2019, 68, 303-308.	0.7	14
13	Phagocytic Efficiency of Monocytes and Macrophages Obtained From Sydney Blood Bank Cohort Members Infected With an Attenuated Strain of HIV-1. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2003, 34, 445-453.	0.9	11
14	Loss of hepatitis E virus in Australian blood donors: possible implications for blood transfusion safety. <i>Transfusion</i> , 2018, 58, 485-492.	0.8	10
15	Intraoral human herpes viruses detectable by PCR in majority of patients. <i>Oral Diseases</i> , 2021, 27, 378-387.	1.5	9
16	Novel Drexelviridae bacteriophage KMI8 with specific lytic activity against <i>Klebsiella michiganensis</i> and its biofilms. <i>PLoS ONE</i> , 2021, 16, e0257102.	1.1	9
17	No evidence for widespread <i>Babesia microti</i> transmission in Australia. <i>Transfusion</i> , 2019, 59, 2368-2374.	0.8	8
18	Characterization of Novel Lytic Bacteriophages of <i>Achromobacter marplantis</i> Isolated from a Pneumonia Patient. <i>Viruses</i> , 2020, 12, 1138.	1.5	8

#	ARTICLE	IF	CITATIONS
19	Case Cluster of Necrotizing Fasciitis and Cellulitis Associated with Vein Sclerotherapy. <i>Emerging Infectious Diseases</i> , 2008, 14, 180-181.	2.0	7
20	The infectious disease blood safety risk of Australian hemochromatosis donations. <i>Transfusion</i> , 2016, 56, 2934-2940.	0.8	7
21	Multi-site implementation of whole genome sequencing for hospital infection control: A prospective genomic epidemiological analysis. <i>The Lancet Regional Health - Western Pacific</i> , 2022, 23, 100446.	1.3	6
22	Understanding occult hepatitis C infection. <i>Transfusion</i> , 2020, 60, 2144-2152.	0.8	4
23	Health service impact of testing for respiratory pathogens using cartridge-based multiplex array versus molecular batch testing. <i>Pathology</i> , 2018, 50, 758-763.	0.3	3
24	Exploring beyond the limit: How comparative stochastic performance affects retesting outcomes in six commercial SARS CoV-2 nucleic acid amplification tests. <i>Journal of Clinical Virology Plus</i> , 2022, 2, 100079.	0.4	1